GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Seer SEER · USD

Health Care · US listing · 🇺🇸 United States

Compare

1.39

-3.82%

Close of 19 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Seer — daily SEER Delayed
Market value
$79.6m
Last close × shares
Volume
245k
Shares, 19 Nov 2026

About Seer

From its filings with the US Securities and Exchange Commission

SEC filings

Seer is based in Redwood City, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker SEER. The SEC classifies its business as laboratory analytical instruments. In the fiscal year to 31 December 2025, it reported revenue of $16.6m and a net loss of $73.6m. At that date it held total assets of $296.1m and shareholders' equity of $259.3m.

In its own words

Our mission is to imagine and pioneer new ways to decode the biology of the proteome to improve human health. Through our product, the Proteograph® Product Suite (Proteograph), we provide researchers with unbiased, deep, rapid and large-scale access to the proteome, enabling biological discovery that has historically been impractical. With our pioneering proprietary engineered nanoparticle (NP) technology and the Proteograph Product Suite, we provide the most complete, precise, and scalable platform for deep, unbiased proteomics to power population-scale studies and data-driven biology.

Proteins are the functional drivers of biology and the primary targets of most approved drugs. Unlike DNA, which is largely static over an individual’s lifetime, the proteome is dynamic, reflecting real-time biological processes, disease states, and responses to therapeutic intervention. However, the molecular diversity of the proteome, arising from transcription, RNA processing, translation, post-translational modifications (PTMs), and protein–protein interactions, has historically limited researchers’ ability to comprehensively characterize protein biology at scale. Traditional proteomic approaches have forced researchers to choose between depth and throughput: unbiased methods that lack scalability, or scalable methods that are targeted, epitope-dependent, and unable to resolve protein variants with sufficient precision.

Quoted from its 10-K, filed 2 Mar 2026. Read the filing on SEC.gov ↗

More about Seer →

How it makes its money

Revenue, year to 31 Dec 2024

  • Service [Member] $3.0m · 20.9%
  • Product [Member] $2.3m · 16.2%
  • Grant and Other $223,000 · 1.6%

Latest on Seer

Our reporting

Next results

4 Mar 2027

Due on 4 Mar 2027. Analysts expect earnings of -0.22 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Seer's ticker?

Seer trades as SEER on its US listing, under ISIN US81578P1066.

What was Seer's last closing price?

1.39 on 19 Nov 2026. The figure is in USD and is never converted.

When does Seer next report results?

Results are expected on 10 Nov 2026, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
SEC filings and our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.